UPDATE: FDA Grants Fast Track Designation to Johnson & Johnson’s Investigational Therapy, Nipocalimab, for Adults with Systemic Lupus Erythematosus

by Lupus Foundation, Ohio | Mar 12, 2026

The Fast Track designation was supported by positive topline results from its Phase 2b JASMINE study.

This post was originally published on this site

Recent Blog Postings

UPDATE: FDA Grants Fast Track Designation to Johnson & Johnson’s Investigational Therapy, Nipocalimab, for Adults with Systemic Lupus Erythematosus
Update: Gazyva® significantly reduces disease activity in adults with systemic lupus erythematosus
Women’s History Month: Women Leading Lupus Research

Categories

Blog
Lupus Foundation of America
News & Events
Patient Stories
Research News